Hazel B Nichols1, Chelsea Anderson, Alexandra J White, Ginger L Milne, Dale P Sandler. 1. From the aDepartment of Epidemiology, University of North Carolina Gillings School of Global Public Health, Chapel Hill, NC; bEpidemiology Branch, National Institute of Environmental Health Sciences, National Institutes of Health, Durham, NC; and cVanderbilt University, Nashville, TN.
Abstract
BACKGROUND: Detrimental effects of oxidative stress are widely recognized, but induction of apoptosis and senescence may also have benefits for cancer prevention. Recent studies suggest oxidative stress may be associated with lower breast cancer risk before menopause. METHODS: We conducted a nested case-control study (N = 457 cases, 910 controls) within the NIEHS Sister Study cohort of 50,884 women. Premenopausal women ages 35-54 were eligible for selection. We matched controls 2:1 to cases on age and enrollment year and were breast cancer-free at the time of the corresponding case's diagnosis. Oxidative stress was measured by urinary F2-isoprostane and metabolite (15-F2t-isoprostane-M) concentrations. Odds ratios (OR) and 95% confidence intervals (CIs) were calculated with multivariable conditional logistic regression. RESULTS: After multivariable adjustment for body mass index (BMI) and other potential confounders, the OR for breast cancer comparing the >90th (≥2.94 ng/mgCr) to <25th percentile (1.01 ng/mgCr) was 1.1 (CI: 0.65, 1.7) for F2-isoprostane and 0.70 (CI: 0.43, 1.1) for the metabolite. Higher metabolite concentrations were associated with lower breast cancer risk among women who were also premenopausal (353 cases, OR: 0.59, CI: 0.34, 1.0) or <46 years (82 cases, OR: 0.15, CI: 0.06, 0.42) at diagnosis. ORs for the metabolite and breast cancer were inverse among women with BMI 18.5-24.9 kg/m (OR: 0.47, CI: 0.18, 1.2, 208 cases) and >30 kg/m (OR: 0.71, CI: 0.30, 1.7, 107 cases), but not among women with BMI 25-29.9 kg/m (OR: 0.98, CI: 0.39, 2.5, 138 cases). CONCLUSIONS: Together with other studies, our results support a possible inverse association between oxidative stress and premenopausal breast cancer risk.
BACKGROUND: Detrimental effects of oxidative stress are widely recognized, but induction of apoptosis and senescence may also have benefits for cancer prevention. Recent studies suggest oxidative stress may be associated with lower breast cancer risk before menopause. METHODS: We conducted a nested case-control study (N = 457 cases, 910 controls) within the NIEHS Sister Study cohort of 50,884 women. Premenopausal women ages 35-54 were eligible for selection. We matched controls 2:1 to cases on age and enrollment year and were breast cancer-free at the time of the corresponding case's diagnosis. Oxidative stress was measured by urinary F2-isoprostane and metabolite (15-F2t-isoprostane-M) concentrations. Odds ratios (OR) and 95% confidence intervals (CIs) were calculated with multivariable conditional logistic regression. RESULTS: After multivariable adjustment for body mass index (BMI) and other potential confounders, the OR for breast cancer comparing the >90th (≥2.94 ng/mgCr) to <25th percentile (1.01 ng/mgCr) was 1.1 (CI: 0.65, 1.7) for F2-isoprostane and 0.70 (CI: 0.43, 1.1) for the metabolite. Higher metabolite concentrations were associated with lower breast cancer risk among women who were also premenopausal (353 cases, OR: 0.59, CI: 0.34, 1.0) or <46 years (82 cases, OR: 0.15, CI: 0.06, 0.42) at diagnosis. ORs for the metabolite and breast cancer were inverse among women with BMI 18.5-24.9 kg/m (OR: 0.47, CI: 0.18, 1.2, 208 cases) and >30 kg/m (OR: 0.71, CI: 0.30, 1.7, 107 cases), but not among women with BMI 25-29.9 kg/m (OR: 0.98, CI: 0.39, 2.5, 138 cases). CONCLUSIONS: Together with other studies, our results support a possible inverse association between oxidative stress and premenopausal breast cancer risk.
Authors: María Elena Martínez; Elizabeth T Jacobs; John A Baron; James R Marshall; Tim Byers Journal: J Natl Cancer Inst Date: 2012-04-25 Impact factor: 13.506
Authors: Steffen Loft; Anja Olsen; Peter Møller; Henrik E Poulsen; Anne Tjønneland Journal: Cancer Epidemiol Biomarkers Prev Date: 2013-05-08 Impact factor: 4.254
Authors: J D Morrow; B Frei; A W Longmire; J M Gaziano; S M Lynch; Y Shyr; W E Strauss; J A Oates; L J Roberts Journal: N Engl J Med Date: 1995-05-04 Impact factor: 91.245
Authors: Myron Gross; Michael Steffes; David R Jacobs; Xinhua Yu; Linda Lewis; Cora E Lewis; Catherine M Loria Journal: Clin Chem Date: 2004-10-28 Impact factor: 8.327
Authors: Kristen D Brantley; Oana A Zeleznik; Barbra A Dickerman; Raji Balasubramanian; Clary B Clish; Julian Avila-Pacheco; Bernard Rosner; Rulla M Tamimi; A Heather Eliassen Journal: Br J Cancer Date: 2022-06-18 Impact factor: 9.075
Authors: Yong-Moon Mark Park; Nitin Shivappa; Joshua Petimar; M Elizabeth Hodgson; Hazel B Nichols; Susan E Steck; James R Hébert; Dale P Sandler Journal: Int J Cancer Date: 2021-04-27 Impact factor: 7.316